-
Sep 16, 2021
Antengene Selected as a Constituent of the FTSE Global Equity Index Series
-
Aug 24, 2021
Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
-
Aug 09, 2021
Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets
-
Aug 02, 2021
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
-
Jul 22, 2021
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
-
Jul 14, 2021
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
